KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Common Equity: 2011-2025

Historic Common Equity for Travere Therapeutics (TVTX) over the last 14 years, with Sep 2025 value amounting to $73.6 million.

  • Travere Therapeutics' Common Equity rose 341.56% to $73.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.6 million, marking a year-over-year increase of 341.56%. This contributed to the annual value of $59.1 million for FY2024, which is 70.58% down from last year.
  • Latest data reveals that Travere Therapeutics reported Common Equity of $73.6 million as of Q3 2025, which was up 124.64% from $32.7 million recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' Common Equity peaked at $362.7 million during Q1 2021, and registered a low of -$30.5 million during Q3 2024.
  • Moreover, its 3-year median value for Common Equity was $73.6 million (2025), whereas its average is $94.8 million.
  • Its Common Equity has fluctuated over the past 5 years, first spiked by 368.62% in 2023, then plummeted by 110.89% in 2024.
  • Travere Therapeutics' Common Equity (Quarterly) stood at $302.1 million in 2021, then crashed by 85.82% to $42.9 million in 2022, then skyrocketed by 368.62% to $200.8 million in 2023, then crashed by 70.58% to $59.1 million in 2024, then spiked by 341.56% to $73.6 million in 2025.
  • Its last three reported values are $73.6 million in Q3 2025, $32.7 million for Q2 2025, and $32.8 million during Q1 2025.